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(A) Response of the yeast ERα 
cytosensor, ERβ cytosensor and 
the yeast cytosensor that          
express both the ERα and the 
ERβ after exposures for 4h to 17 
β-estradiol. (B) Response of the 
yeast ERα  cytosensor to            
dierent substances after 4h                
exposure period: 17 β-estradiol 
(E2), β-estradiol 3-benzoate 
(E2-benz), zearalenone (z-
lenone), genistein, estrone (E1) 
or estriol.
In silico molecular docking can be a cheap and fast 
strategy to estimate the binding free energies, and 
consequently the dissociation constants, for a set of 
compounds with respect to their putative targets. 
Interesting targets for EAS are the ligand binding 
domains (LBD) of the human nuclear receptors for 
the sex hormones, i.e. the estrogen, androgen,     
progesterone, and of the (gluco)corticoid receptor1.
The Horizon 2020 project EuroMix 
(http://euromixproject.eu) aims to establish and    
disseminate new, ecient and validated strategies 
for the risk assessment of mixtures, while limiting 
the use of test animals. The present work deals with 
a part of EuroMix that is intended to set up a testing     
approach for mixtures of endocrine active                
chemicals, focusing on estrogenic eects.
For that purpose, a combined Adverse             
Outcome Pathway (AOP) was constructed,           
including Molecular Initiating Events, Key 
Events, and Adverse Outcome (reproductive 
dysfunction). Using this combined AOP as        
framework, cognate in silico and in vitro tools as 
well as the in vivo conrmation studies were     
selected, i.e. in silico: h-ER and h-AR docking; in 
vitro: cell-based ER and AR transcriptional         
activation bioassays and the H295R                      
steroidogenesis assay; and in vivo: the Fish 
Sexual Development Test (FSDT, OECD Test No. 
234) and a rat study, examining in (male)            
ospring a number of parameters, such as     
anogenital distance, cryptorchidism, and 
nipple retention. 
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Our preliminary work has been focused just on compounds with 
anities higher than the natural hormone ones. Here we reported 
a comparison between computational and experimental data on 
the estrogenic system, but a similar approach can be followed for 
the other investigated targets.
So far,  in silico and in vitro testing of endocrine active reference 
chemicals show a good correlation between the in silico                    
determined binding energies and the in vitro measured hormonal 
activities.
The rst prioritization pipeline is aimed at computing the anity of all 
tested compounds with respect the selected targets. Anity can be 
expressed as binding free energy or dissociation constant. No intrinsic 
activity estimation is provided by this pipeline, making it impossible to 
classify the tested compounds as agonists or antagonists, without any 
further  evaluation.
